within Pharmacolibrary.Drugs.ATC.L;

model L04AH02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.14666666666666667,
    adminDuration  = 600,
    adminMass      = 0.002,
    adminCount     = 1,
    Vd             = 0.11,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009383333333333332,
    Tlag           = 25.74
  );

  annotation(Documentation(
    info ="<html><body><p>Everolimus is an orally available mTOR inhibitor used for the treatment of various cancers (including renal cell carcinoma, breast cancer, and neuroendocrine tumors) and for prevention of organ rejection after transplantation. It is currently approved by regulatory authorities for such uses.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic model in adult solid organ transplant recipients (kidney transplant), both male and female, after oral administration.</p><h4>References</h4><ol><li><p>Kirchner, GI, et al., &amp; Manns, MP (2004). Clinical pharmacokinetics of everolimus. <i>Clinical pharmacokinetics</i> 43(2) 83–95. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200443020-00002&quot;>10.2165/00003088-200443020-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14748618/&quot;>https://pubmed.ncbi.nlm.nih.gov/14748618</a></p></li><li><p>Mueller-Schoell, A, et al., &amp; Kloft, C (2021). Therapeutic drug monitoring of oral targeted antineoplastic drugs. <i>European journal of clinical pharmacology</i> 77(4) 441–464. DOI:<a href=&quot;https://doi.org/10.1007/s00228-020-03014-8&quot;>10.1007/s00228-020-03014-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33165648/&quot;>https://pubmed.ncbi.nlm.nih.gov/33165648</a></p></li><li><p>Combes, FP, et al., &amp; Nedelman, J (2018). Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex. <i>Journal of pharmacokinetics and pharmacodynamics</i> 45(5) 707–719. DOI:<a href=&quot;https://doi.org/10.1007/s10928-018-9600-2&quot;>10.1007/s10928-018-9600-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29992479/&quot;>https://pubmed.ncbi.nlm.nih.gov/29992479</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AH02;
